HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (3- (4- (octadecyloxy)phenyl)propionylamino)- 2,4'- oxydibenzoic acid

structure in first source

Also Known As:

VGA1102

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        5-(3-(4-(octadecyloxy)phenyl)propionylamino)-2,4'-oxydibenzoic acid: 1
  - Acyclic Hydrocarbons
    - Alkanes: 241
      - 5-(3-(4-(octadecyloxy)phenyl)propionylamino)-2,4'-oxydibenzoic acid: 1
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - 5-(3-(4-(octadecyloxy)phenyl)propionylamino)-2,4'-oxydibenzoic acid: 1

Experts

1.	Arai, Koshi: 1 article (07/2004)
2.	Hirayama, Noriko: 1 article (07/2004)
3.	Ikeya, Hisao: 1 article (07/2004)
4.	Nakaike, Shiro: 1 article (07/2004)
5.	Nishihara, Sumi: 1 article (07/2004)
6.	Okazaki, Tadayasu: 1 article (07/2004)
7.	Samata, Kazunori: 1 article (07/2004)
8.	Shibuya, Masabumi: 1 article (07/2004)
9.	Tanaka, Makoto: 1 article (07/2004)
10.	Ueda, Yasuji: 1 article (07/2004)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2004 - "These results suggest that VGA1102 inhibits VEGF function resulting in inhibition of tumor angiogenesis, which led to suppression of growth of human tumors transplanted into nude mice." 07/01/2004 - "A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth."
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/01/2004 - "Furthermore, VGA1102 (50 mg/kg, i.p.) administered daily suppressed the growth of nude mice transplanted with LC-6 human non-small-cell lung cancer. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
3.	LC 6